Personalized medicine is a relatively new treatment modality with great potential for combating life-threatening cancers, cardiovascular diseases and genetic disorders. For example, when treating conditions such as cancer, personalized treatments can be more effective compared to generalized treatments like chemotherapy, as they are manufactured specific to a patient’s tumor. Despite their potential, access to these life-saving treatments is currently limited due to complex and expensive manufacturing processes.

Traditional biopharma facilities use process technologies and setups designed to manufacture high-volume batches of identical products. In personalized medicine, however, the target patient populations are very small—sometimes as small as one. Until now, the ability to process a high volume of small batches has been missing.

The NANOme® was developed to address exactly this challenge. It is an aseptic processing system for back-to-back personalized medicine with reliable quality batches. The innovative system transforms what is currently a lengthy process into a procedure that takes just minutes. “Recognizing that the current reliance on open and operator-driven processes for advanced therapies manufacturing needs an overhaul, we have spearheaded the NANOme® system, which takes us one step closer to taking personalized medicine into the mainstream,” said Dr. Setu Kasera, Chief Scientific Officer at LEON.

The NANOme® has already been internationally recognized with an iF Design Award for its novel design and potential to impact patient lives. It is now set to transform the production of personalized medicine, enabling wider access to the patients that need it.